Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

This study has been completed.
Information provided by:
Daiichi Sankyo Inc. Identifier:
First received: September 1, 2005
Last updated: April 8, 2011
Last verified: April 2011
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.

Condition Intervention Phase
Type 2 Diabetes
Drug: Rivoglitazone
Drug: Pioglitazone
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Change in HbA1c

Secondary Outcome Measures:
  • FPG, Lipids, hsCRP, Adiponectin

Enrollment: 441
Study Start Date: December 2004
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes in male or female patients
  • Between 18 and 75 years of age
  • With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization

Exclusion Criteria:

  • Type 1 diabetics or type 2 diabetics currently on insulin therapy
  • Patients unwilling or unable to discontinue their anti-diabetic medication(s)
  • History of ketoacidosis
  • History of therapy with rosiglitazone, troglitazone, pioglitazone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143520

  Show 74 Study Locations
Sponsors and Collaborators
Daiichi Sankyo Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medical monitor, Daiichi Sankyo Identifier: NCT00143520     History of Changes
Other Study ID Numbers: CS0011-203 
Study First Received: September 1, 2005
Last Updated: April 8, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:
Placebo and active control dose response study of rivoglitazone in type 2 diabetics

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on October 26, 2016